Meeting
2021 ASCO Annual Meeting
CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.
Authors
Neeraj Agarwal
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Neeraj Agarwal , Stephane Oudard , Josep M. Piulats , Michael Thomas Schweizer , Aude Flechon , Teresa Alonso Gordoa , Karim Nacerddine , Andrew Lithio , Erica L. Johnston , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04408924.
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS5086)
DOI
10.1200/JCO.2021.39.15_suppl.TPS5086
Abstract #
TPS5086
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith
Poster
2022 ASCO Genitourinary Cancers Symposium
CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel P. Petrylak
First Author: Cristina I. Truica